A Clinical Trial on the Effects of a Combination of Elcatonin (carbocalcitonin) and Conjugated Estrogens on Vertebral Bone Mass in Early Postmenopausal Women

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 1993 Jul 1

PMID 8394192

Citations 12

Authors

M Meschia

M Brincat

P Barbacini

P G Crossignani

W Albisetti

Affiliations

Soon will be listed here.

Abstract

The study was carried out to determine the effect of a combination regimen of a small dose of calcitonin added to conjugated estrogens with medroxyprogesterone acetate on vertebral bone mass in early postmenopausal women. Comparisons were made with groups of women on calcitonin alone, on conjugated estrogens with medroxyprogesterone acetate alone, or on no treatment. The study was carried out over a 2-year period. The results of the study suggest that the combined regimen of calcitonin and estrogens increased vertebral bone mass in early postmenopausal women to a greater extent than calcitonin alone or estrogen alone. Increases in vertebral bone mass of 11.2% after 1 year and 9.2% after 2 years were demonstrated using the combined regimen. Both estrogens alone and calcitonin alone were, however, very effective in preventing rapid bone loss in the postmenopausal women studied.

Citing Articles

Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review.

Ukon Y, Makino T, Kodama J, Tsukazaki H, Tateiwa D, Yoshikawa H Int J Mol Sci. 2019; 20(10).

PMID: 31137666 PMC: 6567245. DOI: 10.3390/ijms20102557.

Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.

Hongo M, Miyakoshi N, Kasukawa Y, Ishikawa Y, Shimada Y J Bone Miner Metab. 2014; 33(4):432-9.

PMID: 25123562 DOI: 10.1007/s00774-014-0603-9.

The use of combination therapy in the treatment of postmenopausal osteoporosis.

Compston J Endocrine. 2011; 41(1):11-8.

PMID: 22038453 DOI: 10.1007/s12020-011-9554-2.

Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys.

Manabe T, Mori S, Mashiba T, Cao Y, Kaji Y, Iwata K J Bone Miner Metab. 2009; 27(3):295-302.

PMID: 19343273 DOI: 10.1007/s00774-009-0046-x.

Combination therapy for osteoporosis: considerations and controversy.

Binkley N, Krueger D Curr Osteoporos Rep. 2005; 3(4):150-4.

PMID: 16303115 DOI: 10.1007/s11914-996-0018-1.

References

Lindsay R, Hart D, Clark D . The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984; 63(6):759-63. View

Melton 3rd L, Kan S, Frye M, Wahner H, OFallon W, Riggs B . Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989; 129(5):1000-11. DOI: 10.1093/oxfordjournals.aje.a115204. View

BURCH J, BYRD Jr B, Vaughn W . The effects of long-term estrogen on hysterectomized women. Am J Obstet Gynecol. 1974; 118(6):778-82. DOI: 10.1016/0002-9378(74)90487-6. View

Stevenson J, Abeyasekera G, Hillyard C, Phang K, MacIntyre I, Campbell S . Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens. Lancet. 1981; 1(8222):693-5. DOI: 10.1016/s0140-6736(81)91973-5. View

Cummings S, Kelsey J, Nevitt M, ODowd K . Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985; 7:178-208. DOI: 10.1093/oxfordjournals.epirev.a036281. View

Aitken J, Hart D, Lindsay R . Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J. 1973; 3(5879):515-8. PMC: 1586943. DOI: 10.1136/bmj.3.5879.515. View

Overgaard K, Hansen M, Jensen S, Christiansen C . Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992; 305(6853):556-61. PMC: 1883290. DOI: 10.1136/bmj.305.6853.556. View

Eastell R, Wahner H, OFallon W, Amadio P, Melton 3rd L, Riggs B . Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. J Clin Invest. 1989; 83(1):168-74. PMC: 303657. DOI: 10.1172/JCI113854. View

MacIntyre I, Stevenson J, Whitehead M, Wimalawansa S, Banks L, Healy M . Calcitonin for prevention of postmenopausal bone loss. Lancet. 1988; 1(8591):900-2. DOI: 10.1016/s0140-6736(88)91712-6. View

10.

Lindsay R, Hart D, Purdie D, Ferguson M, Clark A, Kraszewski A . Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med. 1978; 54(2):193-5. DOI: 10.1042/cs0540193. View

11.

Lindsay R, Hart D, Aitken J, Macdonald E, Anderson J, Clarke A . Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976; 1(7968):1038-41. DOI: 10.1016/s0140-6736(76)92217-0. View

12.

Overgaard K, Christiansen C . Long-term treatment of established osteoporosis with intranasal calcitonin. Calcif Tissue Int. 1991; 49 Suppl:S60-3. DOI: 10.1007/BF02555091. View

13.

GORDAN G . Prevention of bone loss and fractures in women. Maturitas. 1984; 6(3):225-42. DOI: 10.1016/0378-5122(84)90039-2. View

14.

Savvas M, Studd J, Fogelman I, Dooley M, Montgomery J, Murby B . Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ. 1988; 297(6644):331-3. PMC: 1834046. DOI: 10.1136/bmj.297.6644.331. View

15.

Riggs B, Wahner H, Dunn W, Mazess R, Offord K, Melton 3rd L . Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981; 67(2):328-35. PMC: 370572. DOI: 10.1172/JCI110039. View

16.

Horsman A, Gallagher J, Simpson M, Nordin B . Prospective trial of oestrogen and calcium in postmenopausal women. Br Med J. 1977; 2(6090):789-92. PMC: 1631969. DOI: 10.1136/bmj.2.6090.789. View

17.

Weiss N, Ure C, Ballard J, Williams A, Daling J . Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980; 303(21):1195-8. DOI: 10.1056/NEJM198011203032102. View

18.

Ettinger B, Genant H, Cann C . Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985; 102(3):319-24. DOI: 10.7326/0003-4819-102-3-319. View